Sign In   |   Register
Themed Short Track - September/October2018
Share |

Introducing Themed Short Tracks

In SHORT TRACKS we collect 2-4 recent lectures from EAS congresses or courses, putting them together to provide up-to-date perspectives on a given current topic.

This month’s Short Track topic is New and emerging therapies to treat dyslipidaemias and atherosclerosis”. Under this headline, we have gathered the three presentations given at the 86th EAS Congress in Lisbon 2018.


To the SHORT TRACK “New and emerging therapies to treat dyslipidaemias and atherosclerosis" 

These presentations are open for EAS members only. Register as an EAS Individual member, and the whole ACADEMY is open for you.

How to register as an EAS member >>

PCSK9 Inhibition in high risk patients

This presentation is made by Dr. Gabriel Steg, Professor of Cardiology at the University ParisDiderot, and Director of the Coronary Care Unit of Bichat Hospital, Paris, France.

In his presentation, Prof Gabriel Steg, firstly discusses the results of the FOURIER trial and the efficacy of evolocumab, a specific fully human mAb against PCSK9, in reducing the primary and key secondary endpoints in high risk stable patients with established CV disease.

He also presents data on the effect of evolocumab on the primary outcomes in diabetics and PAD patients. He next presents the topline results from the ODYSSEY OUTCOMES trial, in which the efficacy of alirocumab, another specific fully human mAb against PCSK9, in reducing the primary and main secondary endpoints in patients after an ACS, was studied. He concludes that both mAbs reduce CV events in high risk patients and are well tolerated for duration of treatment of up to 5 years.  

To the presentation >>

Anti-Inflammatory Therapy for Atherosclerosis - Theory and Practice


The 2nd presentation included in this Newsletter was given as a Keynote Lecture by Professor Peter
world-wide recognized specialist in vascular biology, atherosclerosis and preventive cardiology at Brigham and Women’s Hospital, Mallinckrodt Professor of Medicine at Harvard Medical School. 

In his lecture, Prof. Peter Libby discusses the important role of inflammation in the pathophysiology of Atherosclerosis and therefore raises the question whether targeted anti-inflammatory therapy can improve cardiovascular outcomes in humans.

He next discusses the proinflammatory actions of IL-1β in the artery wall and the multiple lines of evidence that implicate IL-1β in atherogenesis. Subsequently, Prof. Peter Libby presents canakinumab a high affinity human mAb against human IL-1β and its efficacy to prevent recurrent cardiovascular events as it was revealed from the results of the CANTOS clinical trial. He discusses the results of this trial and points out that lowering inflammation by IL-1β blockade, reduces cardiovascular and total mortality and also reduces fatal lung cancer.    

To the presentation >>

Silencing genes, new targets

Professor Sotirios Tsimikas, Director of Vascular Medicine and Professor of Medicine, University of California San Diego, La Jolla, USA, starts his presentation with a summary on the RNA-based therapeutics to silence genes, including ASOs, siRNA and Aptamers, as well as on the underlying mechanisms. Subsequently his presentation focuses on recent data by his group regarding the specific ASOs targeting the mRNAs of apo(a), apo C-III and ANGPTL3. Τhe clinical efficacy, of these emerging therapies to reduce the levels of atherogenic lipoproteins in humans as well as their safety and tolerability are presenting

To the presentation >>

Membership Software Powered by YourMembership  ::  Legal